Long-term survivors after allogeneic hematopoietic cell transplantation (allo-HCT) are at risk for developing late complications. To assess the feasibility of long-term follow-up (LTFU) system for allo-HCT survivors, we performed a feasibility study at our center. Patients aged 20 or above who received their first allo-HCT at our center were prospectively enrolled. Patients who had recurrent malignancy were not eligible. LTFU visits were scheduled at 1, 3, 6 months and every 1 year after allo-HCT. Regular blood test, performance status, body weight, graft-versus-host disease, pulmonary function, chest X-ray, disease status, thyroid function, bone density and immune recovery were assessed at each visit. Quality of life (QOL) was also assessed using the FACT-BMT and SF-36. Forty-seven patients with a median age of 55 years and a median follow-up of 24 months (range, 3 months to 7 years) were enrolled during the 6-month study period. Proportions of patients who completed scheduled screening tests ranged from 64 to 100%, and 32% of the participants completed all the screening tests. Fifty-seven percent of participants returned the QOL questionnaires. In conclusion, the LTFU system was feasible at our center, although a more systematic ordering system and tools to capture specific problems after allo-HCT are warranted.